摘要
目的:观察重组人干扰素α-1b和利巴韦林联合治疗小儿手足口病的临床疗效。方法:对106例手足口病患儿随机分为两组各53例,在对症治疗的基础上,对照组予利巴韦林10～15mg/kg,1次/d静脉滴注,连续3d,治疗组加用重组人干扰素α-1b肌肉注射,4个月～2岁6μg/(次.d),2～6岁10μg/(次.d),共3d。有合并细菌感染者加用抗生素治疗。结果:治疗组发热和皮疹消退时间比对照组短,总有效率治疗组86.79%,对照组64.15%,两组比较差异有统计学意义(χ2=4.63,P<0.05)。结论:干扰素α-1b和利巴韦林联合治疗小儿手足口病疗效满意。
Objective：To observe the clinical effects for hand-feet-mouth disease （HFMD） treated with α-1 b interferon. Methods： One hundred and six children suffered from HFMD were divided into a treatment group and a control group randomly. The treatment group （53 cases） received α-1b interferon for im and ribavirin for iv, and the control group （53 cases） were given ribavirin for iv. Results： The periods of fever and rash were shorter in treatment group. The total effects were 86.79% and 64.15% in treatment group and the control group respectively （X^2 = 4. 63, P 〈 0.05 ）. Conclusions： The clinical effects for HFMD treated with combination of α-1 b-interferon and ribavirin was better than that of ribavirin.
出处
《儿科药学杂志》
CAS
2010年第1期31-32,共2页
Journal of Pediatric Pharmacy
关键词
干扰素
利巴韦林
手足口病
Interferon
Ribavirin
Hand-feet-mouth disease
